NCT05114889View on ClinicalTrials.gov

Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

BSI-045B

BSI-045B will be administered weekly, subcutaneously

Trial Locations (1)

Unknown

Scientia Clinical Research, Randwick

Sponsors

Lead Sponsor

Biosion, Inc.

Collaborators (1)

Southern Star Research
All Listed Sponsors
collaborator

Southern Star Research

INDUSTRY

lead

Biosion, Inc.

INDUSTRY

NCT05114889 - Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter